Suchit H Patel1, Andreas Rimner1, Amanda Foster1, Zhigang Zhang2, Kaitlin M Woo2, Helena A Yu3, Gregory J Riely3, Abraham J Wu4. 1. Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, United States. 2. Departments of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, United States. 3. Departments of Thoracic Oncology, Memorial Sloan Kettering Cancer Center, New York, United States. 4. Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, United States. Electronic address: wua@mskcc.org.
Abstract
OBJECTIVES: Patients with metastatic EGFR-mutant (mEGFRmt) NSCLC have favorable survival when treated with erlotinib. We hypothesized that treatment failure in most patients is limited to initial sites of disease, in which case incorporating local therapy such as radiation might further delay progression. We therefore analyzed patterns and predictors of failure in a large cohort of such patients. MATERIALS AND METHODS: We reviewed 189 patients treated with erlotinib for mEGFRmt NSCLC. We classified first pattern of failure as involving initial sites only (ISF), new sites only (NSF), or the combination (CSF), and used competing-risks regression to identify factors associated with ISF, progression and overall survival (OS). We also separately analyzed intracranial and intrathoracic failure. RESULTS: Of 171 patients who progressed, 103 (60.2%) had ISF, 30 (17.5%) had NSF, and 38 (22.2%) had CSF. Younger age and lack of initial CNS involvement independently correlated with ISF, with a trend for higher T and N stage. Higher T and N stage was also a significant predictor of progression. Factors predicting shorter OS were female gender, weight loss, initial intracranial involvement, and ≥4 extracranial metastases. Intrathoracic progression was a component of first failure in 61%, and three-year cumulative incidence of brain metastasis was 30%. CONCLUSION: The main pattern of progression in mEGFRmt NSCLC on erlotinib is in the initial sites of disease. Younger patients and those without brain involvement are particularly likely to develop ISF. This suggests a role for incorporating local therapy into treatment of selected patients with mEGFRmt NSCLC.
OBJECTIVES:Patients with metastatic EGFR-mutant (mEGFRmt) NSCLC have favorable survival when treated with erlotinib. We hypothesized that treatment failure in most patients is limited to initial sites of disease, in which case incorporating local therapy such as radiation might further delay progression. We therefore analyzed patterns and predictors of failure in a large cohort of such patients. MATERIALS AND METHODS: We reviewed 189 patients treated with erlotinib for mEGFRmt NSCLC. We classified first pattern of failure as involving initial sites only (ISF), new sites only (NSF), or the combination (CSF), and used competing-risks regression to identify factors associated with ISF, progression and overall survival (OS). We also separately analyzed intracranial and intrathoracic failure. RESULTS: Of 171 patients who progressed, 103 (60.2%) had ISF, 30 (17.5%) had NSF, and 38 (22.2%) had CSF. Younger age and lack of initial CNS involvement independently correlated with ISF, with a trend for higher T and N stage. Higher T and N stage was also a significant predictor of progression. Factors predicting shorter OS were female gender, weight loss, initial intracranial involvement, and ≥4 extracranial metastases. Intrathoracic progression was a component of first failure in 61%, and three-year cumulative incidence of brain metastasis was 30%. CONCLUSION: The main pattern of progression in mEGFRmt NSCLC on erlotinib is in the initial sites of disease. Younger patients and those without brain involvement are particularly likely to develop ISF. This suggests a role for incorporating local therapy into treatment of selected patients with mEGFRmt NSCLC.
Authors: David M Jackman; Beow Y Yeap; Lecia V Sequist; Neal Lindeman; Alison J Holmes; Victoria A Joshi; Daphne W Bell; Mark S Huberman; Balazs Halmos; Michael S Rabin; Daniel A Haber; Thomas J Lynch; Matthew Meyerson; Bruce E Johnson; Pasi A Jänne Journal: Clin Cancer Res Date: 2006-07-01 Impact factor: 12.531
Authors: Stephanie Heon; Beow Y Yeap; Neal I Lindeman; Victoria A Joshi; Mohit Butaney; Gregory J Britt; Daniel B Costa; Michael S Rabin; David M Jackman; Bruce E Johnson Journal: Clin Cancer Res Date: 2012-06-25 Impact factor: 12.531
Authors: David A Palma; Joseph K Salama; Simon S Lo; Suresh Senan; Tom Treasure; Ramaswamy Govindan; Ralph Weichselbaum Journal: Nat Rev Clin Oncol Date: 2014-06-24 Impact factor: 66.675
Authors: Gregory N Gan; Andrew J Weickhardt; Benjamin Scheier; Robert C Doebele; Laurie E Gaspar; Brian D Kavanagh; D Ross Camidge Journal: Int J Radiat Oncol Biol Phys Date: 2014-01-22 Impact factor: 7.038
Authors: Andrew J Weickhardt; Benjamin Scheier; Joseph Malachy Burke; Gregory Gan; Xian Lu; Paul A Bunn; Dara L Aisner; Laurie E Gaspar; Brian D Kavanagh; Robert C Doebele; D Ross Camidge Journal: J Thorac Oncol Date: 2012-12 Impact factor: 15.609
Authors: Kyle E Rusthoven; Susan F Hammerman; Brian D Kavanagh; Michael J Birtwhistle; Mark Stares; D Ross Camidge Journal: Acta Oncol Date: 2009 Impact factor: 4.089
Authors: Helena A Yu; Camelia S Sima; James Huang; Stephen B Solomon; Andreas Rimner; Paul Paik; M Catherine Pietanza; Christopher G Azzoli; Naiyer A Rizvi; Lee M Krug; Vincent A Miller; Mark G Kris; Gregory J Riely Journal: J Thorac Oncol Date: 2013-03 Impact factor: 15.609
Authors: Gregory J Riely; William Pao; Duykhanh Pham; Allan R Li; Naiyer Rizvi; Ennapadam S Venkatraman; Maureen F Zakowski; Mark G Kris; Marc Ladanyi; Vincent A Miller Journal: Clin Cancer Res Date: 2006-02-01 Impact factor: 12.531
Authors: Sandra P D'Angelo; Bernard Park; Christopher G Azzoli; Mark G Kris; Valerie Rusch; Marc Ladanyi; Maureen F Zakowski Journal: J Thorac Cardiovasc Surg Date: 2010-10-08 Impact factor: 6.439
Authors: S A Laurie; S Banerji; N Blais; S Brule; P K Cheema; P Cheung; N Daaboul; D Hao; V Hirsh; R Juergens; J Laskin; N Leighl; R MacRae; G Nicholas; D Roberge; J Rothenstein; D J Stewart; M S Tsao Journal: Curr Oncol Date: 2019-02-01 Impact factor: 3.677